FOLFOX4新辅助化疗方案治疗进展期胃癌效果观察

目的观察FOLFOX4新辅助化疗方案在进展期胃癌综合治疗中的作用。方法50例临床确诊的进展期胃癌患者分为2组,对照组30例采用外科手术加辅助化疗,观察组20例采用FOLFOX4为主的新辅助化疗-手术-术后辅助化疗),观察新辅助化疗对进展期胃癌的作用和毒性反应并比较2组无肿瘤残留(Residual 0,R0)切除率,手术并发症发生率和生存率。结果观察组20例对FOLFOX4化疗方案耐受较好,完全缓解2例(10%),部分缓解12例(60%),总有效率(CR+PR)为70%,18例(90%)完成了R0切除;对照组30例中有19例(63.3%)完成了R0切除;2组患者R0切除率相比较差异有统计学意义(P<0.05);术后并发症发生率相比差异无统计学意义(P>0.05);观察组与对照组的生存率比较无统计学意义(P>0.05)。结论FOLFOX4新辅助化疗方案毒性反应较低,能提高进展期胃癌R0切除率,不增加手术并发症,未能提高进展期胃癌患者的生存率。

Effects of FOLFOX4 neoadjuvant chemotherapy protocol on advanced gastric cancer

Objective To observe the effects of FOLFOX4 neoadjuvant chemotherapy protocol on advanced gastric cancer.Methods 50 patients with advanced gastric cancer were randomly divided into two groups:control group(30 cases,surgery-adjuvant chemotherapy) and observation group(20 cases,FOLFOX4 neoadjuvant chemotherapy protocol-surgery-postoperative adjuvant chemotherapy).The effect and toxic reaction of FOLFOX4 on the patients with advanced gastric cancer were observed,and the R0 resection rate,complications incidence,survival rate were compared between two groups.Results In observation group,2 cases(10%) were complete remission(CR),12 cases(60%)were partial remission(PR),total effective rate was 70%.There were 18 patients(90%) were achieved Residual 0(R0) resection in observation group as compared with 19 patients(63.3%) were achieved R0 resection in control group(P<0.05).There was no significant change in complications incidenceand survival rate between two groups(P>0.05).Conclusion FOLFOX4 neoadjuvant chemotherapy protocol is low toxic reaction.It can improve R0 resection rate of advanced gastric cancer,complications correlated with surgery are not increased.But it can′t improve the survival rate.